论文部分内容阅读
目的探讨肾透明细胞癌患者血清微小RNA(miR)-106b的表达水平及其临床意义。方法选择肾透明细胞癌患者45例(肾透明细胞癌组)及健康正常人30例(对照组),收集肾透明细胞癌患者术前、术后1周、1个月及对照组的血清样本,利用实时荧光定量反转录聚合酶链反应检测血清miR-106b相对表达水平。比较两组血清miR-106b表达水平,分析血清miR-106b表达水平与肾透明细胞癌患者临床病理特征的关系,采用受试者工作特征(ROC)曲线分析血清miR-106b对肾透明细胞癌的诊断效能。结果肾透明细胞癌组术前和术后1周的血清miR-106b表达量高于术后1个月及对照组(P<0.05);肾透明细胞癌组术后1个月与对照组比较,差异无统计学意义(P>0.05)。不同性别、年龄段、肿瘤直径、Fuhrman分级患者的血清miR-106b表达水平比较,差异均无统计学意义(P>0.05)。ROC曲线分析结果显示,血清miR-106b诊断肾透明细胞癌的曲线下面积为0.876(P<0.05),最佳诊断阈值为2.08,敏感度为86.7%,特异度为80.0%。结论血清miR-106b的高表达与肾透明细胞癌密切相关,可作为肾透明细胞癌的潜在生物标记物。
Objective To investigate the expression of serum microRNA (miR) -106b in patients with clear cell renal cell carcinoma and its clinical significance. Methods 45 patients with clear cell renal cell carcinoma (renal clear cell carcinoma group) and 30 normal healthy controls (control group) were selected. The serum samples of renal clear cell carcinoma patients before operation, 1 week after operation, 1 month after operation and control group , The relative expression level of serum miR-106b was detected by real-time fluorescence quantitative reverse transcription polymerase chain reaction. The level of serum miR-106b was compared between the two groups. The relationship between the level of serum miR-106b and the clinicopathological features of renal clear cell carcinoma was analyzed. The receiver operating characteristic (ROC) curve was used to analyze the effect of serum miR-106b on renal clear cell carcinoma Diagnostic efficiency. Results The serum levels of miR-106b in renal clear cell carcinoma group were significantly higher than those in control group (P <0.05) at 1 month after operation and at 1 month after operation in renal clear cell carcinoma group compared with those in control group , The difference was not statistically significant (P> 0.05). The levels of miR-106b in patients with different gender, age, tumor diameter and Fuhrman grading were not significantly different (P> 0.05). ROC curve analysis showed that the area under the curve of serum miR-106b in the diagnosis of renal clear cell carcinoma was 0.876 (P <0.05), the best diagnosis threshold was 2.08, the sensitivity was 86.7% and the specificity was 80.0%. Conclusion The high expression of serum miR-106b is closely related to clear cell renal cell carcinoma and may be a potential biomarker for clear cell renal cell carcinoma.